John Franklin Fowler - Jul 24, 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
CEO, Director
Signature
/s/ Marc Belsky, Attorney-in-Fact
Stock symbol
KZR
Transactions as of
Jul 24, 2023
Transactions value $
$0
Form type
4
Date filed
7/26/2023, 04:59 PM
Previous filing
Jan 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -175K -100% 0 Jul 24, 2023 Common Stock 175K $22.85 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Award +175K 175K Jul 24, 2023 Common Stock 175K $2.28 Direct F1, F2
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -200K -100% 0 Jul 24, 2023 Common Stock 200K $3.29 Direct F2, F3
transaction KZR Employee Stock Option (right to buy) Award +200K 200K Jul 24, 2023 Common Stock 200K $2.28 Direct F2, F3
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -1.2M -100% 0 Jul 24, 2023 Common Stock 1.2M $5.45 Direct F2, F4
transaction KZR Employee Stock Option (right to buy) Award +1.2M 1.2M Jul 24, 2023 Common Stock 1.2M $2.28 Direct F2, F4
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -500K -100% 0 Jul 24, 2023 Common Stock 500K $14.55 Direct F2, F5
transaction KZR Employee Stock Option (right to buy) Award +500K 500K Jul 24, 2023 Common Stock 500K $2.28 Direct F2, F5
transaction KZR Employee Stock Option (right to buy) Disposed to Issuer -580K -100% 0 Jul 24, 2023 Common Stock 580K $6.84 Direct F2, F6
transaction KZR Employee Stock Option (right to buy) Award +580K 580K Jul 24, 2023 Common Stock 580K $2.28 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.
F2 On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
F3 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2020, subject to the Reporting Person continuing to provide service through each such date.
F4 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
F5 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date.
F6 One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date.